The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN
Phase of Trial: Phase IV
Latest Information Update: 31 May 2016
Price : $35 *
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Multifocal motor neuropathy
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.